Pediatric super-refractory status epilepticus treated with allopregnanolone

Eileen Broomall, Jo Anne E. Natale, Michele Grimason, Joshua Goldstein, Craig M. Smith, Celia Chang, Stephen Kanes, Michael A. Rogawski, Mark S. Wainwright*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Super-refractory status epilepticus is a life-threatening condition. Resistance to benzodiazepine and barbiturate treatment for this disorder is thought to be due to internalization of synaptic c-aminobutyric acid (GABA)A receptors, and withdrawal of benzodiazepines and barbiturates during treatment often triggers seizure recurrence. The neurosteroid allopregnanolone acts as a positive allosteric modulator of synaptic and extrasynaptic GABAA receptors. Here we describe the use of allopregnanolone in 2 pediatric patients with superrefractory status epilepticus. This treatment allowed the general anesthetic infusions to be weaned with resolution of status epilepticus. This is the first report of allopregnanolone use to treat status epilepticus in children.

Original languageEnglish (US)
Pages (from-to)911-915
Number of pages5
JournalAnnals of neurology
Issue number6
StatePublished - Dec 1 2014

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Pediatric super-refractory status epilepticus treated with allopregnanolone'. Together they form a unique fingerprint.

Cite this